DNTH103
Sponsors
Dianthus Therapeutics Inc.
Conditions
Chronic Inflammatory Demyelinating PolyneuropathyGeneralized Myasthenia GravisMultifocal Motor Neuropathygeneralized Myasthenia gravis
Phase 2
A PHASE 2, RANDOMIZED, BLINDED, PLACEBOCONTROLLED, STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOMETRICS, AND EFFICACY OF DNTH103 IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS (MAGIC)
RecruitingCTIS2024-512865-15-00
Start: 2024-09-03Target: 54Updated: 2025-10-27
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults with Multifocal Motor Neuropathy (MOMENTUM)
RecruitingCTIS2024-513128-40-00
Start: 2025-02-06Target: 11Updated: 2026-01-12
Phase 3
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
RecruitingCTIS2024-517529-26-00
Start: 2025-08-04Target: 156Updated: 2026-01-26
A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients with Generalized Myasthenia Gravis (EMERGE)
Not yet recruitingCTIS2026-525298-38-00
Target: 23Updated: 2026-09-29